| Pharmaceutical Information |
| Drug Name |
Sevelamer |
| Drug ID |
BADD_D02012 |
| Description |
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. |
| Indications and Usage |
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis. |
| Marketing Status |
approved |
| ATC Code |
V03AE02 |
| DrugBank ID |
DB00658
|
| KEGG ID |
D08512
|
| MeSH ID |
D000069603
|
| PubChem ID |
3085017
|
| TTD Drug ID |
D03MZQ
|
| NDC Product Code |
Not Available |
| UNII |
941N5DUU5C
|
| Synonyms |
Sevelamer | GT335-012 | GT335 012 | GT335012 | Sevelamer Hydrochloride | Hydrochloride, Sevelamer | RenaGel | Sevelamer Carbonate | Carbonate, Sevelamer |
|
| Chemical Information |
| Molecular Formula |
C6H12ClNO |
| CAS Registry Number |
52757-95-6 |
| SMILES |
C=CCN.C1C(O1)CCl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
